Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 12/20 | 0.41 |
| ▸ | SCD | O00767 | 3/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.40 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.40 |
| ▸ | CLPP | Q16740 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6696978 | 0.86 | PTGER4 (0.46) | PTGER4SCD | |
| SCHEMBL6704025 | 0.81 | SCD (0.44) | PTGER4S1PR3SCDCACNA1GCACNA1H | |
| SCHEMBL6700327 | 0.81 | CLPP (0.43) | PTGER4S1PR3SCDCACNA1GCACNA1H | |
| SCHEMBL6699931 | 0.78 | CLPP (0.38) | CLPP | |
| SCHEMBL6701897 | 0.76 | SCD (0.52) | PTGER4SCD | |
| SCHEMBL6705194 | 0.75 | SMN1; SMN2 (0.47) | PTGER4S1PR3SCD | |
| SCHEMBL6696733 | 0.74 | MMP13 (0.49) | PTGER4 | |
| SCHEMBL6697984 | 0.74 | ALDH1A1 (0.36) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL6292798 | 0.74 | PTGER4 (0.40) | PTGER4S1PR3CACNA1GCACNA1HCACNA1I | |
| Picolamine SCHEMBL6818745 | 0.73 | S1PR3 (0.40) | S1PR3SCDCLPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004014916-A1 | PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | PTGER4 1609/4885S1PR3 1772/4885SCD 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.